2021 IPO

Aura Biosciences Stock

Development of drugs by using tumor targeted Pseudovirions

Sign up today and learn more about Aura Biosciences Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Aura Biosciences Stock

Aura Biosciences, Inc. is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. Aura's NanoSmart drug delivery system aims to solve critical issues in drug delivery by encapsulating therapies within protein nanoparticles engineered for precise targeting, immune system evasion and efficient cellular uptake Aura combines the expertise of leading European and US research institutions with the flexibility and efficiency of a dedicated team of in-house scientists, deal-makers and world class advisors. The company is located in Cambridge, Massachusetts.

Funding History

September 2010$1.4M
August 2011$3.0M
December 2012$3.2M
January 2014$1.3M
August 2014$4.0M
March 2015$21.0M
September 2016$8.0M
December 2017$30.0M
April 2019$40.0M


Senior Vice President of Development

Stephen Monks

Vice President of Clinical Development

Denis O’Shaughnessy

Founder and CEO

Elisabet de los Pinos

Senior Vice President, R&D Operations

Michele Keough

Chief Medical Officer

Cadmus Rich

Chief Financial Officer

Julie Feder

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: